Mycophenolate Mofetil

Mycophenolate mofetil (RS 61443) is the morpholinoethylester proagent of Mycophenolic acid. Mycophenolate mofetil inhibits de novo purine synthesis via the inhibition of inosine monophosphate dehydrogenase (IMPDH) . Mycophenolate mofetil shows selective lymphocyte antiproliferative effects involve both T and B cells, preventing antibody formation[1].

Product Specifications

CAS Number

[128794-94-5]

Product Name Alternative

RS 61443; TM-MMF

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Bacterial; Drug Metabolite; Endogenous Metabolite

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mycophenolate-mofetil.html

Concentration

10mM

Purity

99.83

Solubility

1M NaOH : 33.33 mg/mL (ultrasonic; adjust pH to 12 with 1M NaOH) |DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(OCCN1CCOCC1)CC/C(C)=C/CC2=C(O)C3=C(COC3=O)C(C)=C2OC

Molecular Formula

C23H31NO7

Molecular Weight

433.49

Precautions

H302, H315, H319, H335

References & Citations

[1]Simmons WD, et al. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection. Drug Saf. 1997;17 (2) :75-92.|[2]Fulton B, et al. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51 (2) :278-298.